Does datopotamab deruxtecan improve survival for Hormone Receptor-Positive Breast Cancer?
Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate that targets TROP-2, a protein on cancer cells. In the TROPION-Breast01 trial, it showed a meaningful improvement in progression-free survival (time without cancer growth) compared to standard chemotherapy for metastatic HR-positive/HER2-negative breast cancer. However, when researchers looked at overall survival (how long patients lived), there was no significant benefit. This means that while the drug may delay cancer progression, it did not extend life in this study.
What the research says
The TROPION-Breast01 trial randomly assigned patients with metastatic HR-positive/HER2-negative breast cancer to receive either datopotamab deruxtecan or investigator's choice of chemotherapy (such as eribulin or capecitabine). The study found that datopotamab deruxtecan significantly improved progression-free survival, but the final overall survival analysis showed no statistically significant difference between the two groups (hazard ratio 1.01, 95% CI 0.83-1.22, P=0.9445) 1. This means the drug did not help patients live longer overall compared to standard chemotherapy.
Other treatments have shown different results in HR-positive breast cancer. For example, trastuzumab deruxtecan (a different antibody-drug conjugate) improved progression-free survival in patients with HR-positive, HER2-low metastatic breast cancer 4. Additionally, a large meta-analysis found that statin use was associated with a 23% reduction in recurrence risk and a 23% reduction in mortality in HR-positive breast cancer patients 2. Immunotherapy, however, did not significantly improve overall response rate in HR-positive breast cancer, though it did improve complete response rates 3.
It is important to note that the TROPION-Breast01 trial had an imbalance in subsequent treatments: more patients in the chemotherapy arm later received other antibody-drug conjugates (like trastuzumab deruxtecan or sacituzumab govitecan), which may have affected the overall survival results 1. This means that the lack of survival benefit might partly be due to effective later treatments in the control group.
What to ask your doctor
- What are the potential benefits and risks of datopotamab deruxtecan for my specific cancer type and treatment history?
- How does the lack of overall survival benefit from datopotamab deruxtecan compare to other available treatments, such as trastuzumab deruxtecan or chemotherapy?
- Are there other options, like statins or immunotherapy, that might be appropriate for my situation?
- What clinical trials are available for HR-positive breast cancer that I might be eligible for?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.